期刊
BIOANALYSIS
卷 7, 期 16, 页码 2105-2117出版社
FUTURE SCI LTD
DOI: 10.4155/bio.15.101
关键词
-
资金
- Universidade Feevale
- Novartis
- FAPERGS PPSUS [1153-2551/13-9]
Background: Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml(-1). DBS can increase access to IM therapeutic drug monitoring. Results: IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40 degrees C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1). Conclusion: IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据